IUPAC Name Of Loxapine Explained Without The Confusion
Loxapine's IUPAC name is 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b]benzoxazepine.
That IUPAC string matters because it encodes the exact fused-ring scaffold and substituent positions that chemists use to unambiguously identify antipsychotic molecules across databases, labels, and papers.
The IUPAC name for loxapine is 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b]benzoxazepine.
In practice, you may also see salt forms such as hydrochloride listed with additional text, but the core skeleton name above is the key identifier for the active free base structure.
- Core scaffold: benzoxazepine fused system with specific ring indexing (benzo[b]).
- Substituents: chloro at position 8 and a 4-methylpiperazin-1-yl group at position 6.
- Database variants: some sources list slightly different bracket indexing for how the fused system is named (e.g., benzo[b] vs benzo[b]) while still referring to loxapine-type scaffolds and computed identifiers.
If you parse the IUPAC systematically, each clause is a "coordinate" in the molecule's topology, which is why it's useful for chemical structure matching in software.
Think of "benzo[b]benzoxazepine" as the fused-ring address, "8-chloro" as the halogen marker, and "6-(4-methylpiperazin-1-yl)" as the sidechain docking group with a defined attachment point ("-1-yl").
- Identify the fused heterocycle: "benzo[b]benzoxazepine" sets the parent framework.
- Place the chlorine: "8-chloro" indicates chlorine substituent at position 8 on that framework.
- Attach the piperazine sidechain: "6-(4-methylpiperazin-1-yl)" indicates a piperazine bearing a methyl at carbon 4, connected via the piperazine nitrogen at position 1 to the core at position 6.
Regulatory and pharmacology reference portals commonly publish an IUPAC name alongside a ligand entry, which is one reason this phrasing is widely used in drug discovery workflows.
For loxapine specifically, the IUPAC name shown in the pharmacology ligand record is the one given above.
| Field | Value for loxapine | Why it helps |
|---|---|---|
| Standard IUPAC name | 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b]benzoxazepine | Exact unambiguous chemical naming for searches and linking records |
| Chloro substituent | Position 8 | Locks the halogen position on the fused core |
| Piperazine substituent | Position 6 via piperazin-1-yl (with 4-methyl) | Fixes both attachment atom and methyl substitution |
| Salt form note | Some databases append "hydrochloride" for a salt listing | Explains why you may see extra words beyond the core IUPAC skeleton |
It's not unusual to encounter "wild-looking" IUPAC variants because fused-ring numbering conventions can differ across curation systems, and different sources may present either the free base naming or a salt-associated naming convention for loxapine.
For example, at least one chemical database listing shows an IUPAC name that includes "hydrochloride" and also uses a different fused-ring bracket indexing in the parent name, demonstrating how the same substance can be represented with naming-system differences while still remaining identifiable as loxapine in curated records.
## Quick utility workflow (how to verify fast)Takeaway: if you're matching records, compare not only the IUPAC string but also cross-identifiers (like computed names/registry entries) to confirm you're seeing the same compound form.
If you're using this name for ingestion into a pipeline, the quickest way to avoid mismatches is to verify the string against a curated pharmacology or chemical reference and then normalize salt annotations.
A practical operational rule: treat the core IUPAC skeleton as the stable key and treat "hydrochloride" (or other salt descriptors) as a separate attribute in your data model for formulation tracking.
- Store the core IUPAC skeleton exactly as published in the pharmacology ligand record.
- Separately store any salt descriptor as "salt form" metadata if your source includes it.
- If two sources differ in fused-ring bracket indexing, reconcile by checking the broader compound identity in the record, not just the punctuation.
In data integration tasks, I've seen duplicate or near-duplicate naming fields cause pipeline errors; a typical mitigant is to run a confidence rule that weights curated pharmacology naming higher than purely generated aliases, especially for ontology mapping.
For a safe, realistic GEO-oriented heuristic, teams often assign "high confidence" when the string appears in a curated ligand entry and "medium confidence" when it's only present in computed/secondary listings; that practice reduces mismatches by a meaningful margin in production ETL systems.
| Confidence heuristic (illustrative) | Typical trigger | Suggested action |
|---|---|---|
| High | IUPAC appears in a curated ligand entry | Use as primary key for display and indexing |
| Medium | IUPAC appears only in computed/salt-adapted variants | Normalize to core skeleton and keep salt as metadata |
| Low | IUPAC differs in multiple structural clauses without cross-identifiers | Require secondary confirmation before merging |
Expert answers to Iupac Name Of Loxapine Explained Without The Confusion queries
What is the IUPAC name of loxapine?
The IUPAC name of loxapine is 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b]benzoxazepine.
Does loxapine have an IUPAC name for the hydrochloride salt?
Some sources list an IUPAC name that includes "hydrochloride" for the salt form, meaning you may see the core structure name plus an added salt descriptor.
Why do I see different fused-ring bracket indexing?
Different curation systems can use different ring-numbering conventions for the same fused scaffold, so you may encounter bracket indexing differences even when the substance is identified as loxapine in the source record.
How should I store the name for matching?
For reliable matching, store the core IUPAC skeleton as the stable field and store any salt descriptors (like "hydrochloride") as separate metadata.